T. Rowe Price Associates
PRPH

T. Rowe Price Associates’s ProPhase Labs PRPH Stock Holding History

T. Rowe Price Associates’s Portfolio PRPH Stock Details PRPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,686
Closed -$7K – 3104
2025
Q2 		$7K Sell
1,686
-44
-3% -$147 ﹤0.01% 3055
2025
Q1 		$7K Hold
1,730
– – ﹤0.01% 3030
2024
Q4 		$13K Hold
1,730
– – ﹤0.01% 3003
2024
Q3 		$42K Hold
1,730
– – ﹤0.01% 2951
2024
Q2 		$73K Hold
1,730
– – ﹤0.01% 2797
2024
Q1 		$112K Hold
1,730
– – ﹤0.01% 2759
2023
Q4 		$79K Hold
1,730
– – ﹤0.01% 2744
2023
Q3 		$76K Hold
1,730
– – ﹤0.01% 2711
2023
Q2 		$126K Buy
+1,730
New +$141K ﹤0.01% 2647

Other funds holding PRPH

SC
Sykon Capital Harrison, New York $325M AUM 19.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AWP
Accretive Wealth Partners Parsippany, New Jersey $412M AUM 15.82% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
CD
Chapin Davis Baltimore, Maryland $569M AUM 145.59% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates's PRPH Position: Q3 2025 in Review

T. Rowe Price Associates sold out of ProPhase Labs (PRPH) in Q3 2025, closing a stake of 1,686 shares — an estimated $7K sold.

T. Rowe Price Associates first reported a position in PRPH in Q2 2023 and held it in 9 quarters. The position peaked at $126K in Q2 2023. 28 funds tracked by Wall St. Rank hold PRPH as of Q3 2025.

  • T. Rowe Price Associates reported no remaining ProPhase Labs position as of Q3 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 1,686 ProPhase Labs shares in Q3 2025, an estimated $7K.
  • T. Rowe Price Associates first reported a position in ProPhase Labs in Q2 2023 and held it in 9 quarters.
  • T. Rowe Price Associates's ProPhase Labs position peaked at $126K in Q2 2023.
  • 28 funds tracked by Wall St. Rank held ProPhase Labs as of Q3 2025.

Based on T. Rowe Price Associates's 13F filing for Q3 2025, filed 14 Nov 2025.